Clinical trials: Postmenopausal
Postmenopausal Osteoporosis
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
The primary objective of this study is to characterize safety and tolerability of romosozumab in postmenopausal women with osteoporosis and a high risk of fracture in India.
- Trial name
- NCT06079476
- Testing
- Romosozumab
- Where
- 10 sites in India
- Volunteers
- 100 people
- Sponsor
- Amgen
Post Menopausal Osteoporosis
Evaluation of Adherence With Bisphosphonates and Calcium and Vitamin D Supplements in Women With Postmenopausal Osteoporosis
This study aims to evaluate the adherence of patients to combined treatment with bisphosphonates and calcium and vitamin D supplements, which is one of the usual treatments for postmenopausal osteoporosis.
- Trial name
- OSTEOAD (NCT07105163)
- Where
- 20 sites in Spain
- Volunteers
- 230 people
- Sponsor
- Procare Health Iberia S.L.
Osteoporosis, Postmenopausal
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis
The purpose of this study is to demonstrate similar efficacy and safety between TVB-009 and Prolia® (denosumab)
- Trial name
- NCT04729621
- Testing
- TVB-009, Prolia®
- Where
- 78 sites in United States, Bulgaria and 8 more
- Volunteers
- 332 people
- Sponsor
- Teva Pharmaceuticals USA
Postmenopausal Osteoporosis, Low Bone Mass
Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass
This is a randomized, double-blind, placebo- and active-controlled Phase II study evaluating the efficacy and safety of TST002 injection (a humanized monoclonal antibody) in postmenopausal women with osteoporosis or low bone…
- Trial name
- NCT07806331
- Testing
- Denosumab
- Volunteers
- 110 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Postmenopausal Women Osteoporosis
A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis
This study is a multicenter, randomized, double-blinded, parallel-group Phase III clinical study to compare the clinical efficacy, safety, and immunogenicity of 9MW0311 and Prolia® in Chinese postmenopausal women with…
- Trial name
- NCT06804590
- Testing
- 9MW0311, Prolia®
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Postmenopausal Women With Osteoporosis
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
This is a multicenter, randomized, open-label, parallel-controlled Phase II study designed to evaluate the differences in safety among four different dosing regimens of SAL056.
- Trial name
- NCT07579936
- Testing
- SAL056 56.5μg, Intervention Group 1, Intervention Group 2
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Healthy Postmenopausal Women, Absorption
A Clinical Study to Evaluate the Absorption, Metabolism, and Excretion of Oral [14C]GS1-144 in Healthy Postmenopausal Female Participants
This is a single-center, non-randomized, open-label, single-dose clinical PK study in healthy postmenopausal female participants.
- Conditions
- Healthy Postmenopausal Women, Absorption, Metabolism, Excretion
- Trial name
- NCT07537231
- Testing
- [14C]GS1-144
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Osteoporosis, Postmenopausal, Bone Density, Low
The Effect of the Probiotic Strains on Bone Mineral Density in Postmenopausal Women
Osteoporosis is a systemic condition characterized by low bone mass and altered bone tissue microarchitecture, with the resulting greater bone fragility leading to fractures.
- Trial name
- NCT06375668
- Testing
- Probiotic
- Where
- 3 sites in Poland
- Volunteers
- 170 people
- Sponsor
- Nordic Biotic Sp. z o.o.
Healthy Postmenopausal Women
SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females
This is an Open-label, Sequential dosing, Single Ascending Dose (SAD) Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of KSHN001126 in Healthy Human Post-Menopausal Female Volunteers.
- Trial name
- NCT06467201
- Testing
- KSHN001126 150mg, KSHN001126 300mg, KSHN001126 600mg
- Where
- 2 sites in United States, India
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Amneal Pharmaceuticals, LLC
Healthy Postmenopausal Women
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers
The goal of this clinical trial is to evaluate if KSHN001034 demonstrates safety, tolerability, and a comparable pharmacokinetic (PK) profile to the reference product, Faslodex® (fulvestrant), which is used for the treatment of…
- Trial name
- NCT06995482
- Testing
- KSHN001034, Fulvestrant
- Where
- 2 sites in United States, India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kashiv BioSciences, LLC
Postmenopausal Osteoporosis
A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®
The Study will be conducted to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women with Osteoporosis.
- Trial name
- NCT05405725
- Testing
- ENZ215, Prolia
- Where
- 48 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 504 people
- Sponsor
- Enzene Biosciences Ltd.
Postmenopausal Osteoporosis
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
The primary objective of this study is to determine the effect of treatment with AGA2118 versus placebo at Month 12 on lumbar spine bone mineral density (BMD) in postmenopausal women with low bone mass.
- Trial name
- ARTEMIS (NCT06577935)
- Testing
- AGA2118
- Where
- 23 sites in United States, Argentina and 2 more
- Volunteers
- 379 people
- Sponsor
- Angitia Biopharmaceuticals
Postmenopausal Women
A Study of Single Dose of BL0175 in Postmenopausal Women
The goal of this clinical trial is to learn the safety and PK of the single dose of BL0175 Injection in postmenopausal women and to compare that with a single dose of Fulvestrant Injection.
- Trial name
- NCT07366632
- Testing
- BL0175, Fulvestrant
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Postmenopausal, Healthy Adult Female Participants
A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of LAE102 in healthy postmenopausal women
- Trial name
- LAE102 (NCT06908707)
- Testing
- LAE102 SC, LAE102 IV
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Laekna Limited
Perimenopause, Perimenopausal Depression
A Trial to Investigate the Accuracy of a Wearable Device in Collecting Data Related to Perimenopausal Symptoms in Women
The goal of this observational study is to investigate the accuracy of the device in characterizing perimenopausal and menopausal symptoms including vasomotor symptoms, anxiety, sleep quality compared to self-reported symptoms…
- Conditions
- Perimenopause, Perimenopausal Depression, Perimenopausal Insomnia, Perimenopausal Women
- Trial name
- NCT07022925
- Where
- Canada
- Volunteers
- 110 people
- Sponsor
- IdentifyHer Limited
Postmenopausal Women With Osteoporosis
Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis
This is a randomized, double-blind, multicenter, parallel-arm, Phase 3 study to compare the efficacy, PK (Pharmacokinetic), PD (Pharmacodynamic), safety, and immunogenicity of Bmab 1000 and Prolia® in postmenopausal women with…
- Trial name
- DEVOTE (NCT05345691)
- Testing
- Bmab 1000, Prolia®
- Where
- United Kingdom
- Volunteers
- 479 people
- Sponsor
- Biocon Biologics UK Ltd
Postmenopausal Osteoporosis
Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year
- Trial name
- NCT05630768
- Testing
- Risedronate Sodium 35 MG [Actonel], Calcium Vitamin D combination
- Where
- South Korea
- Volunteers
- 149 people
- Sponsor
- Dong-A ST Co., Ltd.
Healthy Postmenopausal Women
A Bioavailability Study of GS1-144 Tablets in Healthy Postmenopausal Women
To evaluate the pharmacokinetic (PK) characteristics of GS1-144 tablets and the relative bioavailability of the two preparations in healthy postmenopausal female subjects in China.
- Trial name
- NCT06983925
- Testing
- GS1-144 Tablet with new preparation (T), GS1-144 Tablet with present preparation (R)
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Postmenopausal Women With Osteoporosis at High Risk of Fracture
A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®
This study is a multicenter, randomized, double-blind comparative study to valuating the efficacy and safety of QL1206 and Prolia® in postmenopausal women with osteoporosis at high risk of fracture.
- Trial name
- NCT07062978
- Testing
- QL1206, Prolia®
- Where
- China
- Volunteers
- 278 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Postmenopausal Women With Osteoporosis
To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk
To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women with Osteoporosis at High Fracture Risk
- Trial name
- NCT07028320
- Testing
- SAL056 (56.5μg), Alendronate
- Where
- China
- Volunteers
- 493 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.